在本次大会上,一项题为“Validation of the 2022 European Leukemianet Risk Stratification of Acute Myeloid Leukemia(2022年欧洲白血病网(ELN)急性髓系白血病(AML)风险分层的验证)”的研究入选壁报展示(P4310),为AML风险分层带来重要启示。...
[4] NCCN Guidelines Version 1.2022 Acute Myeloid Leukemia (Age≥18 years). [5] Wakita S, Sakaguchi M, Oh I, Kako S, Toya T,et al.Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemia. Blood Adv. 2022 Jan 11...
Challenging the Adverse Label: Diverse Outcomes of ELN 2022 Adverse Cytogenetic Subgroups in Acute Myeloid Leukemia Patients Undergoing Allogeneic Hematopoietic Cell Transplantation in First Remission: On Behalf of the EBMT Acute Leukemia Working Party...
在本次大会上,一项题为“Validation of the 2022 European Leukemianet Risk Stratification of Acute Myeloid Leukemia(2022年欧洲白血病网(ELN)急性髓系白血病(AML)风险分层的验证)”的研究入选壁报展示(P4310),为AML风险分层带来重要启示。本期特整理如下,供大家提前阅览。 研究简介 背景 AML在临床结局和疾病生物学...
2022_ELN_Favorable_Code.Rmd R code for replicating results in Archer et al., "Improving risk stratification for 2022 European LeukemiaNet favorable-risk patients with acute myeloid leukemia" hdcuremodels The hdcuremodels R package was used for fitting high-dimensional mixture cure models. A vignett...
The 2017 version of the European LeukemiaNet (ELN) recommendations, by integrating cytogenetics and mutational status of specific genes, divides patients with acute myeloid leukemia into 3 prognostically distinct risk categories: favorable (ELN2017-FR), intermediate (ELN2017-IR), and adverse (ELN2017...
ACUTE myeloid leukemiaFor most patients with acute myeloid leukemia (AML), an allogeneic hematopoietic stem cell transplantation (HSCT) offers the highest chance of cure. Recently, the European LeukemiaNet (ELN) published updated recommendations on the diagnosis and risk classification in AML based on...
Outcome Prediction By the New 2022 European Leukemia Net (ELN) Genetic-Risk Classification for Adult Patients (Pts) with Acute Myeloid Leukemia (AML): An Alliance Studydoi:10.1182/blood-2022-167352Krzysztof Mrózek MDPhDJessica Kohlschmidt PhD...
acute myeloid leukemiaAMLWHOICCELNclassificationComprehensive analyses of the molecular heterogeneity of acute myelogenous leukemia, AML, particularly when malignant cells retain normal karyotype, has significantly evolved. In 2022, significant revisions were introduced in the World Health Organization (WHO) ...
[5]Lachowiez C A, Long N, Saultz J, et al. Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia[J]. Blood Advances, 2023, 7(9): 1899-1909. [6]Attardi E, Savi A, Borselli...